Pediatric dosing and body size in biotherapeutics

Pharmaceutics

Volumn 2, Issue 4, 2010, Pages 389-418

  Shi, Rong ^a   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

Dosing; Pediatric; Peptides; Proteins

Indexed keywords

ALEMTUZUMAB; ALPHAN1 INTERFERON; ASPARAGINASE MACROGOL; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; DROTRECOGIN; ENFUVIRTIDE; ERYTHROPOIETIN; ETANERCEPT; GEMTUZUMAB; HUMAN INSULIN; INFLIXIMAB; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; LB 03002; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PALIVIZUMAB; PEGINTERFERON ALPHA2A; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH HORMONE; RECOMBINANT INTERLEUKIN 11; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AGE DISTRIBUTION; ANEMIA; AREA UNDER THE CURVE; BIOLOGICAL THERAPY; BODY SIZE; BODY SURFACE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CROHN DISEASE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; LUNG DYSPLASIA; MAXIMUM PLASMA CONCENTRATION; PEDIATRICS; REVIEW; SINGLE DRUG DOSE;

EID: 79952162814     PISSN: None     EISSN: 19994923     Source Type: Journal    
DOI: 10.3390/pharmaceutics2040389     Document Type: Review

References (121)

1. Roberts, R.; Rodriguez, W.; Murphy, D.; Crescenzi, T. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 2003, 290, 905-911.
2. Alcorn, J.; McNamara, P.J. Pharmacokinetics in the newborn. Adv. Drug Deliv. Rev. 2003, 55, 667-686.
3. Rodriguez, W.; Selen, A.; Avant, D.; Chaurasia, C.; Crescenzi, T.; Gieser, G.; Di Giacinto, J.; Huang, S.M.; Lee, P.; Mathis, L.; Murphy, D.; Murphy, S.; Roberts, R.; Sachs, H.C.; Suarez, S.; Tandon, V.; Uppoor, R.S. Improving pediatric dosing through pediatric initiatives: What we have learned. Pediatrics 2008, 121, 530-539.
4. Derendorf, H. Pediatrics. http://www.cop.ufl.edu/safezone/pat/pha5128/index.htm (accessed on 30 September 2010).
5. Schoeller, D.A. Changes in total body water with age. Am. J. Clin. Nutr. 1989, 50, 1176-1181; discussion 1231-1175.
6. Peters, A.M.; Henderson, B.L.; Lui, D. Indexed glomerular filtration rate as a function of age and body size. Clin. Sci. (Lond) 2000, 98, 439-444.
7. Hines, R.N. Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol. 2007, 21, 169-175.
8. Koukouritaki, S.B.; Manro, J.R.; Marsh, S.A.; Stevens, J.C.; Rettie, A.E.; McCarver, D.G.; Hines, R.N. Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. 2004, 308, 965-974.
9. Authier, F.; Danielsen, G.M.; Kouach, M.; Briand, G.; Chauvet, G. Identification of insulin domains important for binding to and degradation by endosomal acidic insulinase. Endocrinology 2001, 142, 276-289.
10. Smedsrod, B.; Einarsson, M. Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver. Thromb. Haemost. 1990, 63, 60-66.
11. FDA. Guidance for Industry General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm072114.pdf (accessed on 1 December 2010).
12. Lobo, E.D.; Hansen, R.J.; Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 2004, 93, 2645-2668.
13. Tang, L.; Persky, A.M.; Hochhaus, G.; Meibohm, B. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 2004, 93, 2184-2204.
14. Reilly, R.M.; Sandhu, J.; Alvarez-Diez, T.M.; Gallinger, S.; Kirsh, J.; Stern, H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin. Pharmacokinet. 1995, 28, 126-142.
15. Zito, S.W., Pharmaceutical Biotechnology: A Programmed Text; Technomic Pub.Co.: Lancaster, PA, USA, 1997; pp. 184-186.
16. Tan, A.C.; Russel, F.G.; Thien, T.; Benraad, T.J. Atrial natriuretic peptide. An overview of clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 1993, 24, 28-45.
17. Colburn, W. Peptide, Peptoid, and Protein Pharmacokinetics/Pharmacodynamics; Harvey Whitney Books: Cincinnati, OH, USA, 1991; Volume 3, pp. 94-115.
18. Eppler, S.M.; Combs, D.L.; Henry, T.D.; Lopez, J.J.; Ellis, S.G.; Yi, J.H.; Annex, B.H.; McCluskey, E.R.; Zioncheck, T.F. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin. Pharmacol. Ther. 2002, 72, 20-32.
19. Piscitelli, S.C.; Reiss, W.G.; Figg, W.D.; Petros, W.P. Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations. Clin. Pharmacokinet. 1997, 32, 368-381.
20. Soy, D.; Aweeka, F.T.; Church, J.A.; Cunningham, C.K.; Palumbo, P.; Kosel, B.W.; Sheiner, L.B. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin. Pharmacol. Ther. 2003, 74, 569-580.
21. Toon, S. The relevance of pharmacokinetics in the development of biotechnology products. Eur. J. Drug. Metab. Pharmacokinet. 1996, 21, 93-103.
22. Johnson, V.; Maack, T. Renal extraction, filtration, absorption, and catabolism of growth hormone. Am. J. Physiol. 1977, 233, F185-F196.
23. Rabkin, R.; Ryan, M.P.; Duckworth, W.C. The renal metabolism of insulin. Diabetologia 1984, 27, 351-357.
24. Takagi, A.; Masuda, H.; Takakura, Y.; Hashida, M. Disposition characteristics of recombinant human interleukin-11 after a bolus intravenous administration in mice. J. Pharmacol. Exp. Ther. 1995, 275, 537-543.
25. Carone, F.A.; Peterson, D.R. Hydrolysis and transport of small peptides by the proximal tubule. Am. J. Physiol. 1980, 238, F151-F158.
26. Carone, F.A.; Peterson, D.R.; Flouret, G. Renal tubular processing of small peptide hormones. J. Lab. Clin. Med. 1982, 100, 1-14.
27. Maack, T.; Johnson, V.; Kau, S. T.; Figueiredo, J.; Sigulem, D., Renal filtration, transport, and metabolism of low-molecular-weight proteins: A review. Kidney. Int. 1979, 16, 251-270.
28. Nielsen, S.; Nielsen, J.T.; Christensen, E.I. Luminal and basolateral uptake of insulin in isolated, perfused, proximal tubules. Am. J. Physiol. 1987, 253, F857-F867.
29. Authier, F.; Posner, B.I.; Bergeron, J.J. Endosomal proteolysis of internalized proteins. FEBS Lett. 1996, 389, 55-60.
30. Meibohm, B.; Derendorf, H. Pharmacokinetics and Pharmacodynamics of Biotech Drugs; Wiley-VCH: Weinheim, Germany, 2003; pp. 35-36.
31. Racine-Poon, A.; Botta, L.; Chang, T.W.; Davis, F.M.; Gygax, D.; Liou, R.S.; Rohane, P.; Staehelin, T.; van Steijn, A.M.; Frank, W. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin. Pharmacol. Ther. 1997, 62, 675-690.
32. Schulman, E.S. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am. J. Respir. Crit. Care Med. 2001, 164, S6-11.
33. Kovarik, J.M.; Offner, G.; Broyer, M.; Niaudet, P.; Loirat, C.; Mentser, M.; Lemire, J.; Crocker, J.F.; Cochat, P.; Clark, G.; Gerbeau, C.; Chodoff, L.; Korn, A.; Hall, M. A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokineticdynamic evaluations. Transplantation 2002, 74, 966-971.
34. Kovarik, J.M.; Kahan, B.D.; Rajagopalan, P.R.; Bennett, W.; Mulloy, L.L.; Gerbeau, C.; Hall, M.L. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group. Transplantation 1999, 68, 1288-1294.
35. Kovarik, J.M.; Gridelli, B.G.; Martin, S.; Rodeck, B.; Melter, M.; Dunn, S.P.; Merion, R.M.; Tzakis, A.G.; Alonso, E.; Bucuvalas, J.; Sharp, H.; Gerbeau, C.; Chodoff, L.; Korn, A.; Hall, M. Basiliximab in pediatric liver transplantation: A pharmacokinetic-derived dosing algorithm. Pediatr. Transplant 2002, 6, 224-230.
36. Hocker, B.; Kovarik, J.M.; Daniel, V.; Opelz, G.; Fehrenbach, H.; Holder, M.; Hoppe, B.; Hoyer, P.; Jungraithmayr, T.C.; Kopf-Shakib, S.; Laube, G.F.; Muller-Wiefel, D.E.; Offner, G.; Plank, C.; Schroder, M.; Weber, L.T.; Zimmerhackl, L.B.; Tonshoff, B. Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. Transplantation 2008, 86, 1234-1240.
37. Kovarik, J.M.; Pescovitz, M.D.; Sollinger, H.W.; Kaplan, B.; Legendre, C.; Salmela, K.; Book, B.K.; Gerbeau, C.; Girault, D.; Somberg, K. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. Clin. Transplant 2001, 15, 123-130.
38. Pescovitz, M.D.; Knechtle, S.; Alexander, S.R.; Colombani, P.; Nevins, T.; Nieforth, K.; Bouw, M.R. Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatr. Transplant 2008, 12, 447-455.
39. Saez-Llorens, X.; Castano, E.; Null, D.; Steichen, J.; Sanchez, P.J.; Ramilo, O.; Top, F.H., Jr.; Connor, E. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr. Infect. Dis. J. 1998, 17, 787-791.
40. Saez-Llorens, X.; Moreno, M.T.; Ramilo, O.; Sanchez, P.J.; Top, F.H., Jr.; Connor, E.M. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr. Infect. Dis. J. 2004, 23, 707-712.
41. Burns, J.C.; Best, B.M.; Mejias, A.; Mahony, L.; Fixler, D.E.; Jafri, H.S.; Melish, M.E.; Jackson, M.A.; Asmar, B.I.; Lang, D.J.; Connor, J.D.; Capparelli, E.V.; Keen, M.L.; Mamun, K.; Keenan, G.F.; Ramilo, O. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J. Pediatr. 2008, 153, 833-838.
42. Ruperto, N.; Lovell, D.J.; Cuttica, R.; Wilkinson, N.; Woo, P.; Espada, G.; Wouters, C.; Silverman, E.D.; Balogh, Z.; Henrickson, M.; Apaz, M.T.; Baildam, E.; Fasth, A.; Gerloni, V.; Lahdenne, P.; Prieur, A.M.; Ravelli, A.; Saurenmann, R.K.; Gamir, M.L.; Wulffraat, N.; Marodi, L.; Petty, R.E.; Joos, R.; Zulian, F.; McCurdy, D.; Myones, B.L.; Nagy, K.; Reuman, P.; Szer, I.; Travers, S.; Beutler, A.; Keenan, G.; Clark, J.; Visvanathan, S.; Fasanmade, A.; Raychaudhuri, A.; Mendelsohn, A.; Martini, A.; Giannini, E.H. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007, 56, 3096-3106.
43. Ternant, D.; Mulleman, D.; Degenne, D.; Willot, S.; Guillaumin, J.M.; Watier, H.; Goupille, P.; Paintaud, G. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther. Drug Monit. 2006, 28, 169-174.
44. Cornillie, F.; Shealy, D.; D'Haens, G.; Geboes, K.; Van Assche, G.; Ceuppens, J.; Wagner, C.; Schaible, T.; Plevy, S.E.; Targan, S.R.; Rutgeerts, P. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment. Pharmacol. Ther. 2001, 15, 463-473.
45. St Clair, E.W.; Wagner, C.L.; Fasanmade, A.A.; Wang, B.; Schaible, T.; Kavanaugh, A.; Keystone, E.C. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo- controlled trial. Arthritis Rheum. 2002, 46, 1451-1459.
46. Sleight, B.S.; Chan, K.W.; Braun, T.M.; Serrano, A.; Gilman, A.L. Infliximab for GVHD therapy in children. Bone Marrow Transplant. 2007, 40, 473-480.
47. Buckwalter, M.; Dowell, J.A.; Korth-Bradley, J.; Gorovits, B.; Mayer, P.R. Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J. Clin. Pharmacol. 2004, 44, 873-880.
48. Dowell, J.A.; Korth-Bradley, J.; Liu, H.; King, S.P.; Berger, M.S. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J. Clin. Pharmacol. 2001, 41, 1206-1214.
49. Angiolillo, A.L.; Yu, A.L.; Reaman, G.; Ingle, A.M.; Secola, R.; Adamson, P.C. A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. Pediatr. Blood Cancer 2009, 53, 978-983.
50. Mould, D.R.; Baumann, A.; Kuhlmann, J.; Keating, M.J.; Weitman, S.; Hillmen, P.; Brettman, L.R.; Reif, S.; Bonate, P.L. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br. J. Clin. Pharmacol. 2007, 64, 278-291.
51. Montillo, M.; Tedeschi, A.; Miqueleiz, S.; Veronese, S.; Cairoli, R.; Intropido, L.; Ricci, F.; Colosimo, A.; Scarpati, B.; Montagna, M.; Nichelatti, M.; Regazzi, M.; Morra, E. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J. Clin. Oncol. 2006, 24, 2337-2342.
52. Hale, G.; Rebello, P.; Brettman, L.R.; Fegan, C.; Kennedy, B.; Kimby, E.; Leach, M.; Lundin, J.; Mellstedt, H.; Moreton, P.; Rawstron, A.C.; Waldmann, H.; Osterborg, A.; Hillmen, P. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004, 104, 948-955.
53. Trippett, T.M.; Herzog, C.; Whitlock, J.A.; Wolff, J.; Kuttesch, J.; Bagatell, R.; Hunger, S.P.; Boklan, J.; Smith, A.A.; Arceci, R.J.; Katzenstein, H.M.; Harbison, C.; Zhou, X.; Lu, H.; Langer, C.; Weber, M.; Gore, L. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: A study of the pediatric oncology experimental therapeutic investigators' consortium. J. Clin. Oncol. 2009, 27, 5102-5108.
54. Tan, A.R.; Moore, D.F.; Hidalgo, M.; Doroshow, J.H.; Poplin, E.A.; Goodin, S.; Mauro, D.; Rubin, E.H. Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin. Cancer Res. 2006, 12, 6517-6522.
55. Glade Bender, J.L.; Adamson, P.C.; Reid, J.M.; Xu, L.; Baruchel, S.; Shaked, Y.; Kerbel, R.S.; Cooney-Qualter, E.M.; Stempak, D.; Chen, H.X.; Nelson, M.D.; Krailo, M.D.; Ingle, A.M.; Blaney, S.M.; Kandel, J.J.; Yamashiro, D.J. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J. Clin. Oncol. 2008, 26, 399-405.
56. Gordon, M.S.; Margolin, K.; Talpaz, M.; Sledge, G.W., Jr.; Holmgren, E.; Benjamin, R.; Stalter, S.; Shak, S.; Adelman, D. Phase I safety and pharmacokinetic study of recombinant human anti- vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 2001, 19, 843-850.
57. Lu, J.F.; Bruno, R.; Eppler, S.; Novotny, W.; Lum, B.; Gaudreault, J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother. Pharmacol. 2008, 62, 779-786.
58. Hyams, J.S.; Wilson, D.C.; Thomas, A.; Heuschkel, R.; Mitton, S.; Mitchell, B.; Daniels, R.; Libonati, M.A.; Zanker, S.; Kugathasan, S. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J. Pediatr. Gastroenterol. Nutr. 2007, 44, 185-191.
59. Freeman, B.B.,3rd; Hinds, P.; Iacono, L.C.; Razzouk, B.I.; Burghen, E.; Stewart, C.F. Pharmacokinetics and pharmacodynamics of intravenous epoetin alfa in children with cancer. Pediatr. Blood Cancer 2006, 47, 572-579.
60. Lim, V.S.; DeGowin, R.L.; Zavala, D.; Kirchner, P.T.; Abels, R.; Perry, P.; Fangman, J. Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo- controlled trial. Ann. Intern. Med. 1989, 110, 108-114.
61. Evans, J.H.; Brocklebank, J.T.; Bowmer, C.J.; Ng, P.C. Pharmacokinetics of recombinant human erythropoietin in children with renal failure. Nephrol. Dial. Transplant1991,6,709-714.
62. Widness, J.A.; Veng-Pedersen, P.; Peters, C.; Pereira, L.M.; Schmidt, R.L.; Lowe, L.S. Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J. Appl. Physiol. 1996, 80, 140-148.
63. Ohls, R.K.; Veerman, M.W.; Christensen, R.D., Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. J. Pediatr. 1996, 128, 518-523.
64. Knebel, W.; Palmen, M.; Dowell, J.A.; Gastonguay, M. Population pharmacokinetic modeling of epoetin delta in pediatric patients with chronic kidney disease. J. Clin. Pharmacol. 2008, 48, 837-848.
65. Smith, W.B.; Dowell, J.A.; Pratt, R.D. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clin. Ther. 2007, 29, 1368-1380.
66. Lerner, G.; Kale, A.S.; Warady, B.A.; Jabs, K.; Bunchman, T.E.; Heatherington, A.; Olson, K.; Messer-Mann, L.; Maroni, B.J. Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr. Nephrol. 2002, 17, 933-937.
67. Macdougall, I.C.; Gray, S.J.; Elston, O.; Breen, C.; Jenkins, B.; Browne, J.; Egrie, J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J. Am. Soc. Nephrol. 1999, 10, 2392-2395.
68. Ateshkadi, A.; Johnson, C.A.; Oxton, L.L.; Hammond, T.G.; Bohenek, W.S.; Zimmerman, S.W. Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Am. J. Kidney Dis. 1993, 21, 635-642.
69. Macdougall, I.C.; Roberts, D.E.; Coles, G.A.; Williams, J.D. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin. Pharmacokinet. 1991, 20, 99-113.
70. Blumer, J.; Berg, S.; Adamson, P.C.; Loew, T.; Rossi, G.; Hastings, C. Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. Pediatr. Blood Cancer 2007, 49, 687-693.
71. De Palo, T.; Giordano, M.; Palumbo, F.; Bellantuono, R.; Messina, G.; Colella, V.; Caringella, A.D. Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. Pediatr. Nephrol. 2004, 19, 337-340.
72. Faulkner, L.B.; Tucci, F.; Tamburini, A.; Tintori, V.; Lippi, A.A.; Bambi, F.; Malentacca, F.; Azzari, C.; Gelli, A.M.; Genovese, F.; Bernini, G. G-CSF serum pharmacokinetics during peripheral blood progenitor cell mobilization: Neutrophil count-adjusted dosage might potentially improve mobilization and be more cost-effective. Bone Marrow Transplant. 1998, 21, 1091-1095.
73. Wells, R.J.; Weck, P.K.; Baehner, R.L.; Krivit, W.; Raney, R.B.; Ortega, J.A.; Bernstein, I.O.; Lampkin, B.; Whisnant, J.K.; Sather, H.N., et al. Interferon-alpha n1 in children with recurrent acute lymphocytic leukemia: a phase I study of pharmacokinetics and tolerance. J. Interferon Res. 1988, 8, 309-318.
74. Knost, J.A.; Sherwin, S.A.; Abrams, P.G.; Ochs, J.J.; Foon, K.A.; Williams, R.; Tuttle, R.; Oldham, R.K. The treatment of cancer patients with human lymphoblastoid interferon. A comparison of two routes of administration. Cancer Immunol. Immunother. 1983, 15, 144-148.
75. Schwarz, K.B.; Mohan, P.; Narkewicz, M.R.; Molleston, J.P.; Nash, S.R.; Hu, S.; Wang, K.; Gries, J.M. Safety, efficacy and pharmacokinetics of peginterferon alpha2a (40 kd) in children with chronic hepatitis C. J. Pediatr. Gastroenterol. Nutr. 2006, 43, 499-505.
76. Zeuzem, S.; Feinman, S.V.; Rasenack, J.; Heathcote, E.J.; Lai, M.Y.; Gane, E.; O'Grady, J.; Reichen, J.; Diago, M.; Lin, A.; Hoffman, J.; Brunda, M.J. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 2000, 343, 1666-1672.
77. Gonzalez-Peralta, R.P.; Kelly, D.A.; Haber, B.; Molleston, J.; Murray, K.F.; Jonas, M.M.; Shelton, M.; Mieli-Vergani, G.; Lurie, Y.; Martin, S.; Lang, T.; Baczkowski, A.; Geffner, M.; Gupta, S.; Laughlin, M. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005, 42, 1010-1018.
78. Villar, A.; Aronis, S.; Morfini, M.; Santagostino, E.; Auerswald, G.; Thomsen, H.F.; Erhardtsen, E.; Giangrande, P.L. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004, 10, 352-359.
79. Murry, D.J.; Crom, W.R.; Reddick, W.E.; Bhargava, R.; Evans, W.E. Liver volume as a determinant of drug clearance in children and adolescents. Drug Metab. Disposition 1995, 23, 1110-1116.
80. Klitgaard, T.; Nielsen, T.G. Overview of the human pharmacokinetics of recombinant activated factor VII. Br. J. Clin. Pharmacol. 2008, 65, 3-11.
81. Blanchette, V.S.; Shapiro, A.D.; Liesner, R.J.; Hernandez Navarro, F.; Warrier, I.; Schroth, P.C.; Spotts, G.; Ewenstein, B.M. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J. Thromb. Haemost.2008,6, 1319-1326.
82. Tarantino, M.D.; Collins, P.W.; Hay, C.R.; Shapiro, A.D.; Gruppo, R.A.; Berntorp, E.; Bray, G.L.; Tonetta, S.A.; Schroth, P.C.; Retzios, A.D.; Rogy, S.S.; Sensel, M.G.; Ewenstein, B.M. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: Pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004, 10, 428-437.
83. Gale, R.F.; Hird, M.F.; Colvin, B.T. Management of a premature infant with moderate haemophilia A using recombinant factor VIII. Haemophilia 1998, 4, 850-853.
84. Carlsson, M.; Berntorp, E.; Björkman, S.; Lethagen, S.; Ljung, R. Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia 2007, 3, 96-101.
85. Bolon-Larger, M.; Chamouard, V.; Bressolle, F.; Boulieu, R. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A. Ther. Drug Monit. 2007, 29, 20-26.
86. Bjorkman, S.; Folkesson, A.; Jonsson, S. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur. J. Clin. Pharmacol. 2009, 65, 989-998.
87. Matucci, M.; Messori, A.; Donati-Cori, G.; Longo, G.; Vannini, S.; Morfini, M.; Tendi, E.; Rossi- Ferrini, P.L. Kinetic evaluation of four Factor VIII concentrates by model-independent methods. Scand. J. Haematol. 1985, 34, 22-28.
88. van Dijk, K.; van der Bom, J.G.; Lenting, P.J.; de Groot, P.G.; Mauser-Bunschoten, E.P.; Roosendaal, G.; Grobbee, D.E.; van den Berg, H.M. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005, 90, 494-498.
89. Bjorkman, S.; Folkesson, A.; Berntorp, E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia 2007, 13, 2-8.
90. Ahnstrom, J.; Berntorp, E.; Lindvall, K.; Bjorkman, S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia 2004, 10, 689-697.
91. Bjorkman, S.; Shapiro, A.D.; Berntorp, E. Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia 2001, 7, 133-139.
92. Danne, T.; Datz, N.; Endahl, L.; Haahr, H.; Nestoris, C.; Westergaard, L.; Fjording, M.S.; Kordonouri, O. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr. Diabetes 2008, 9, 554-560.
93. Danne, T. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus. Clin. Ther. 2007, 29 (Suppl. D), S145-S152.
94. Mortensen, H.B.; Lindholm, A.; Olsen, B.S.; Hylleberg, B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur. J. Pediatr. 2000, 159, 483-488.
95. Danne, T.; Becker, R.H.; Heise, T.; Bittner, C.; Frick, A.D.; Rave, K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005, 28, 2100-2105.
96. Malloy, J.; Capparelli, E.; Gottschalk, M.; Guan, X.; Kothare, P.; Fineman, M. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. Clin. Ther. 2009, 31, 806-815.
97. Buse, J.B.; Henry, R.R.; Han, J.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27, 2628-2635.
98. DeFronzo, R.A.; Ratner, R.E.; Han, J.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28, 1092-1100.
99. Kendall, D.M.; Riddle, M.C.; Rosenstock, J.; Zhuang, D.; Kim, D.D.; Fineman, M.S.; Baron, A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28, 1083-1091.
100. Walvoord, E.C.; de la Pena, A.; Park, S.; Silverman, B.; Cuttler, L.; Rose, S.R.; Cutler, G.; Drop, S.; Chipman, J.J. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety. J. Clin. Endocrinol. Metab. 2009, 94, 2052-2059.
101. Peter, F.; Savoy, C.; Ji, H.J.; Juhasz, M.; Bidlingmaier, M.; Saenger, P. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency. Eur. J. Endocrinol. 2009, 160, 349-355.
102. Bidlingmaier, M.; Kim, J.; Savoy, C.; Kim, M.J.; Ebrecht, N.; de la Motte, S.; Strasburger, C.J. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J. Clin. Endocrinol. Metab. 2006, 91, 2926-2930.
103. Kemp, S.F.; Fielder, P.J.; Attie, K.M.; Blethen, S.L.; Reiter, E.O.; Ford, K.M.; Marian, M.; Dao, L.N.; Lee, H.J.; Saenger, P. Pharmacokinetic and pharmacodynamic characteristics of a longacting growth hormone (GH) preparation (nutropin depot) in GH-deficient children. J. Clin. Endocrinol. Metab. 2004, 89, 3234-3240.
104. Houdijk, E.C.; Herdes, E.; Delemarre-Van de Waal, H.A. Pharmacokinetics and pharmacodynamics of recombinant human growth hormone by subcutaneous jet- or needle- injection in patients with growth hormone deficiency. Acta Paediatr. 1997, 86, 1301-1307.
105. Cairo, M.S.; Davenport, V.; Bessmertny, O.; Goldman, S.C.; Berg, S.L.; Kreissman, S.G.; Laver, J.; Shen, V.; Secola, R.; van de Ven, C.; Reaman, G.H. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br. J. Haematol. 2005, 128, 49-58.
106. Aoyama, K.; Uchida, T.; Takanuki, F.; Usui, T.; Watanabe, T.; Higuchi, S.; Toyoki, T.; Mizoguchi, H. Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects. Br. J. Clin. Pharmacol. 1997, 43, 571-578.
107. Yim, D.S.; Zhou, H.; Buckwalter, M.; Nestorov, I.; Peck, C.C.; Lee, H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J. Clin. Pharmacol. 2005, 45, 246-256.
108. Zhou, H.; Buckwalter, M.; Boni, J.; Mayer, P.; Raible, D.; Wajdula, J.; Fatenejad, S.; Sanda, M. Population-based pharmacokinetics of the soluble TNFr etanercept: A clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 2004, 42, 267-276.
109. Lee, H.; Kimko, H.C.; Rogge, M.; Wang, D.; Nestorov, I.; Peck, C.C. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin. Pharmacol. Ther. 2003, 73, 348-365.
110. Wiznia, A.; Church, J.; Emmanuel, P.; Eppes, S.; Rowell, L.; Evans, C.; Bertasso, A. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr. Infect. Dis. J. 2007, 26, 799-805.
111. Church, J.A.; Cunningham, C.; Hughes, M.; Palumbo, P.; Mofenson, L.M.; Delora, P.; Smith, E.; Wiznia, A.; Purdue, L.; Hawkins, E.; Sista, P. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr. Infect. Dis. J. 2002, 21, 653-659.
112. Church, J.A.; Hughes, M.; Chen, J.; Palumbo, P.; Mofenson, L.M.; Delora, P.; Smith, E.; Wiznia, A.; Hawkins, E.; Sista, P.; Cunningham, C.K. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr. Infect. Dis. J. 2004, 23, 713-718.
113. Zhang, X.; Lin, T.; Bertasso, A.; Evans, C.; Dorr, A.; Kolis, S.J.; Salgo, M.; Patel, I. Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatment. J. Clin. Pharmacol. 2007, 47, 510-517.
114. Patel, I.H.; Zhang, X.; Nieforth, K.; Salgo, M.; Buss, N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin. Pharmacokinet. 2005, 44, 175-186.
115. Mould, D.R.; Zhang, X.; Nieforth, K.; Salgo, M.; Buss, N.; Patel, I.H. Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin. Pharmacol. Ther. 2005, 77, 515-528.
116. Vieira Pinheiro, J.P.; Lanversa, C.; Wurthwein, G.; Beier, R.; Casimiro da Palma, J.; von Stackelberg, A.; Boos, J. Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Leuk. Lymphoma.2002,43, 1911-1920.
117. Baillargeon, J.; Langevin, A.M.; Lewis, M.; Thomas, P.J.; Mullins, J.; Dugan, J.; Pollock, B.H. L- asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia. Cancer 2005, 104, 2858-2861.
118. Anderson, B.J.; Allegaert, K.; Holford, N.H. Population clinical pharmacology of children: modelling covariate effects. Eur. J. Pediatr. 2006, 165, 819-829.
119. Anderson, B.J.; Holford, N.H. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol.Toxicol. 2008, 48, 303-332.
120. Anderson, B.J.; Holford, N.H. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 2009, 24, 25-36.
121. Sehgal, N. Hospitalization rate surges 119% in pre-teens due to eating disorders--study. www.themoneytimes.com/featured/20101129/hospitalization-rate-surges-119-preteens-dueeating- disordersstudy-id-10143305.htm (accessed on 3 December 2010).